Twice-Failed, and Yet . . .
Untangling Prochymal's Bid: Data Hint at Osiris Triumph
By Randy Osborne
Monday, June 29, 2009
Mixed interim Phase II data with Prochymal chronic obstructive pulmonary disease - good safety, not-so-great efficacy - laid a ball of confusion on Wall Street's doorstep that prompted sharply differing opinions about the future of the adult mesenchymal stem cell candidate from Osiris Therapeutics Inc.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.